Patent classifications
A61K51/0472
PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
Preparation of metal-pyridine derivative complexes for use in medical imaging
The present invention relates to methods of forming metal-pyridine derivative complexes using pericyclic reactions with metal-1,2,4-triazine derivative complexes and a dienophile as the reactants. The reactants are bioorthogonal and the methods are particularly useful in preparing imaging agents.
PSMA-targeting compounds and uses thereof
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
PSMA-targeting compounds and uses thereof
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
METHODS OF TREATING CANCER
The disclosure pertains to drug delivery conjugates for targeted therapy. The disclosure relates to methods of treating PSMA expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac. The disclosure also relates to methods of treating PSMA-expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac in N patients where stable disease results after treatment with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac.
PSMA-TARGETING COMPOUNDS AND USES THEREOF
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
PSMA-TARGETING COMPOUNDS AND USES THEREOF
Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE
The present disclosure relates to methods to create a robust procedure capable of supplying commercial quantities of a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.